---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-064241"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:25:34.751223+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CorMedix Q2 net loss widens to $11.3M; DefenCath NDA PDUFA date Nov 15, 2023

## Summary
- Net loss of $11.3M ($0.25 per share) vs $7.6M loss in Q2 2022, driven by increased R&D and SG&A.
- Cash and short-term investments $52.4M at June 30; after July equity offering pro forma cash ~$95M.
- DefenCath NDA accepted with PDUFA target date of November 15, 2023; CMS set NTAP up to $17,111 if approved.
- Operating expenses increased 43% to $11.8M; R&D up 49% to $4.8M; SG&A up 39% to $7.0M.
- Strategic initiative with Boston Medical Center to assess CRBSI incidence and health disparities.

## SEC filing metadata
- accession: 0001213900-23-064241
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390023064241/0001213900-23-064241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390023064241/ea183017-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-064241
- JSON: https://secwatch.observer/filing/0001213900-23-064241.json
- Plain text: https://secwatch.observer/filing/0001213900-23-064241.txt

## Key facts
- Earnings Releases
  CorMedix Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 8, 2023, CorMedix Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1410098/000121390023064241/0001213900-23-064241-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.